Vieira R, Azevedo M, Polónio P, Manso C
Clínica Psiquiátrica Universitária, Hospital de Santa Maria, Portugal.
Acta Psychiatr Scand. 1989 Jan;79(1):83-8. doi: 10.1111/j.1600-0447.1989.tb09237.x.
Plasma benzylamine oxidase (BzAO) activity was analysed in a group of 40 schizophrenic patients and compared with that of healthy controls. Although plasma BzAO was significantly decreased in schizophrenics as a whole, when patients were divided into type I (favourable course) and type II (poor course) it was found that the reduced BzAO activity was only observed in type I. Several clinical features were associated with a low BzAO level. The clinical and biological significance of the identification of a biochemical alteration in a subgroup of schizophrenic patients is discussed, and we suggest that the possibility of BzAO being a marker for prognosis in schizophrenia should be further investigated.
对40名精神分裂症患者进行了血浆苄胺氧化酶(BzAO)活性分析,并与健康对照组进行了比较。虽然总体上精神分裂症患者的血浆BzAO显著降低,但当将患者分为I型(病程良好)和II型(病程不佳)时,发现BzAO活性降低仅在I型中观察到。几种临床特征与低BzAO水平相关。讨论了在精神分裂症患者亚组中识别生化改变的临床和生物学意义,并且我们建议应进一步研究BzAO作为精神分裂症预后标志物的可能性。